Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has expanded its exclusive licensing agreements with Ocumension Therapeutics for the commercialization of YUTIQ® and DEXYCU® in Asian markets. Ocumension will pay EyePoint $9.5 million, which covers prior milestone payments for regulatory and commercial sales. This partnership aims to enhance the availability of these therapies in South Korea and Southeast Asia, addressing significant unmet medical needs in ocular diseases. The financial influx will support ongoing clinical developments, including EYP-1901, a potential six-month treatment for wet age-related macular degeneration.
EyePoint Pharmaceuticals (NASDAQ: EYPT) presented data supporting the efficacy of YUTIQ® at the ASRS Virtual Annual Meeting. YUTIQ is a fluocinolone acetonide intravitreal implant for treating chronic, non-infectious uveitis affecting the posterior segment of the eye. The Phase 3 trial involved 129 patients and highlighted a lower recurrence rate of uveitis with YUTIQ compared to sham treatment. Key findings included a 48% reduction in macular edema for YUTIQ patients and improved visual acuity results. YUTIQ is indicated for long-term treatment, providing benefits during the COVID-19 pandemic.
EyePoint Pharmaceuticals (NASDAQ: EYPT) appointed Dr. Jay S. Duker as Chief Strategic Scientific Officer to lead the development of EYP-1901, targeted at wet age-related macular degeneration. Dr. Duker, a renowned retina specialist with over 30 years of experience, will focus on advancing research and pipeline expansion while continuing to practice medicine. He steps down from the Board of Directors to take on this part-time role. The company granted him stock options for 250,000 shares as part of the inducement for his appointment.
EyePoint Pharmaceuticals (NASDAQ:EYPT) announced that CEO Nancy Lurker will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:30 AM ET. The event will be streamed live and an archived replay will be available on the company's website for 90 days. EyePoint is focused on innovative ophthalmic products addressing unmet medical needs, with two commercial products: DEXYCU and YUTIQ. Their pipeline includes EYP-1901, a VEGF inhibitor aimed at treating various serious eye disorders. For more information, visit www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced positive retrospective case study results for DEXYCU® (dexamethasone intraocular suspension) 9% aimed at treating post-operative inflammation after ocular surgeries. Presented at ASCRS 2020, interim data included significant improvements in inflammation metrics among patients. With a projected enrollment of 600 patients, the study confirms DEXYCU's efficacy over traditional steroid drops, enhancing patient adherence and minimizing hospital visits amid pandemic concerns. The findings bolster the perceived advantages of DEXYCU in clinical settings.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported total revenues of $7.5 million for Q1 2020, up from $2.0 million in Q1 2019. Net product revenues reached $4.7 million, driven primarily by $3.6 million from YUTIQ and $1.1 million from DEXYCU. Operating expenses increased to $18.9 million, leading to a net loss of $13.2 million or $0.11 per share. The company has initiated GLP toxicology studies for its EYP-1901 treatment and expects to file an IND application later this year. Cash reserves stand at $26.3 million, supporting operations amid COVID-19 challenges.